Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ornithine phenylacetate - Ocera Therapeutics

Drug Profile

Ornithine phenylacetate - Ocera Therapeutics

Alternative Names: L-Ornithine phenylacetate; MNK 6106; MNK-6105; OCR-002; OP; Ornithine hydrochloride/sodium phenylacetate; Sodium phenylacetate/ornithine hydrochloride; UCL-L1V

Latest Information Update: 28 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University College London
  • Developer Ocera Therapeutics
  • Class Basic amino acids; Diamino amino acids; Esters; Hepatoprotectants; Neuroprotectants; Phenylacetates; Small molecules
  • Mechanism of Action Aminohydrolase modulators; Ammonia scavengers; NF-kappa B modulators; Nitric oxide synthase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatic encephalopathy; Liver failure
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II/III Hepatic encephalopathy
  • Phase II Liver cirrhosis; Liver failure
  • Preclinical Non-alcoholic fatty liver disease

Most Recent Events

  • 30 Oct 2019 Mallinckrodt plans a phase III trial for Hepatic-encephalopathy in November 2019 (NCT04128462) (EudraCT2019-001635-31)
  • 28 Oct 2019 No recent reports of development identified for phase-I development in Hepatic-encephalopathy(Prevention) in USA (IV, Infusion)
  • 01 Dec 2018 Phase-II clinical trials in Liver cirrhosis in USA (PO) (NCT03712280)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top